Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01860170 · ClinicalTrials.gov registry record · Phase 1
Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
A Phase 1 study, sponsored by Corewell Health West.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01860170 is a Phase 1 study that has completed, run by Corewell Health West. The registered enrollment target is 28 participants.
The verdict
NCT01860170, a Phase 1 study, has completed, sponsored by Corewell Health West.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Bortezomib, known commercially as Velcade is safe and tolerated at different dose levels (amounts) with high dose Cyclophosphamide to be used as graft versus host disease prevention after reduced-intensity allogeneic hematopoietic stem cell transplantation.
Interventions
- DRUG Cohort 1-Bortezomib (Velcade ®)
- DRUG Cohort 2-Bortezomib (Velcade ®)
- DRUG Cohort 3-Bortezomib (Velcade ®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2012-04 |
| Est. Completion | 2018-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01860170
The ClinicalTrials.gov registry entry for NCT01860170 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health West, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cohort 1-Bortezomib (Velcade ®) is the first listed.
NCT01860170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01860170 about?
NCT01860170 is a clinical study titled "Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis". The purpose of this study is to determine if Bortezomib, known commercially as Velcade is safe and tolerated at different dose levels (amounts) with high dose Cyclophosphamide to be used as graft versus host disease prevention after reduced-intensity allogeneic hematopoietic stem cell transplantatio...
What is the current status of trial NCT01860170?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2012-04. Estimated completion is 2018-03.
What interventions are being tested in trial NCT01860170?
The interventions under investigation include: Cohort 1-Bortezomib (Velcade ®) (DRUG), Cohort 2-Bortezomib (Velcade ®) (DRUG), Cohort 3-Bortezomib (Velcade ®) (DRUG).
Who is sponsoring clinical trial NCT01860170?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.